Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Clinical implications of Brief Psychiatric Rating Scale scores.

Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R.

Br J Psychiatry. 2005 Oct;187:366-71.

2.

Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.

Takahashi H, Kamata M, Yoshida K, Ishigooka J, Higuchi H.

J Clin Psychiatry. 2006 Oct;67(10):1577-82.

PMID:
17107250
3.

Equipercentile linking of the Brief Psychiatric Rating Scale and the Clinical Global Impression Scale in a catchment area.

Leucht S, Engel RR, Davis JM, Kissling W, Meyer Zur Capellen K, Schmauß M, Messer T.

Eur Neuropsychopharmacol. 2012 Jul;22(7):501-5. doi: 10.1016/j.euroneuro.2011.11.007. Epub 2012 Mar 3.

PMID:
22386773
4.

Linking the PANSS, BPRS, and CGI: clinical implications.

Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR.

Neuropsychopharmacology. 2006 Oct;31(10):2318-25. Epub 2006 Jul 5.

5.

A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.

Crespo-Facorro B, Pérez-Iglesias R, Ramirez-Bonilla M, Martínez-García O, Llorca J, Luis Vázquez-Barquero J.

J Clin Psychiatry. 2006 Oct;67(10):1511-21.

PMID:
17107241
6.

Antipsychotic effects of bretazenil, a partial benzodiazepine agonist in acute schizophrenia--a study group report.

Delini-Stula A, Berdah-Tordjman D.

J Psychiatr Res. 1996 Jul-Aug;30(4):239-50.

PMID:
8905533
7.

Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine.

Molina JD, Toledo-Romero F, López-Rodríguez E, Amorin-Díaz M, Lerma-Carrillo I, López-Muñoz F.

Pharmacopsychiatry. 2011 Jun;44(4):142-7. doi: 10.1055/s-0031-1279728. Epub 2011 Jun 27.

PMID:
21710404
8.

Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.

Olié JP, Spina E, Murray S, Yang R.

Int Clin Psychopharmacol. 2006 May;21(3):143-51.

PMID:
16528136
9.

Practical issues with amisulpride in the management of patients with schizophrenia.

Pani L, Villagrán JM, Kontaxakis VP, Alptekin K.

Clin Drug Investig. 2008;28(8):465-77. Review.

PMID:
18598092
10.

Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.

Dolzan V, Serretti A, Mandelli L, Koprivsek J, Kastelic M, Plesnicar BK.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1562-6. doi: 10.1016/j.pnpbp.2008.05.022. Epub 2008 Jun 24.

PMID:
18573584
11.

Equipercentile linking of the BPRS and the PANSS.

Leucht S, Rothe P, Davis JM, Engel RR.

Eur Neuropsychopharmacol. 2013 Aug;23(8):956-9. doi: 10.1016/j.euroneuro.2012.11.004. Epub 2013 Feb 22.

PMID:
23433639
12.

What does the PANSS mean?

Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR.

Schizophr Res. 2005 Nov 15;79(2-3):231-8. Epub 2005 Jun 27.

PMID:
15982856
13.

The brief psychiatric rating scale: effect of scaling system on clinical response assessment.

Thompson PA, Buckley PF, Meltzer HY.

J Clin Psychopharmacol. 1994 Oct;14(5):344-6.

PMID:
7806691
14.

Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia.

Müller MJ, Wetzel H, Eich FX, Rein W, Puech A, Benkert O; Amisulpride Study Group.

J Clin Psychopharmacol. 2002 Dec;22(6):554-60.

PMID:
12454554
15.

Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms.

Levine SZ, Leucht S.

Schizophr Res. 2013 Apr;145(1-3):125-7. doi: 10.1016/j.schres.2012.12.032. Epub 2013 Feb 8.

PMID:
23394742
16.

On the concept of remission in schizophrenia.

Leucht S, Beitinger R, Kissling W.

Psychopharmacology (Berl). 2007 Nov;194(4):453-61. Epub 2007 Jul 6.

PMID:
17618422
17.

Early prediction of antipsychotic nonresponse among patients with schizophrenia.

Leucht S, Busch R, Kissling W, Kane JM.

J Clin Psychiatry. 2007 Mar;68(3):352-60.

PMID:
17388703
18.

Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.

Harvey PD, Davidson M, White L, Keefe RS, Hirschowitz J, Mohs RC, Davis KL.

Biol Psychiatry. 1996 Oct 15;40(8):755-60.

PMID:
8894068
19.

Clinical relevance of findings in trials of antipsychotics: systematic review.

Lepping P, Sambhi RS, Whittington R, Lane S, Poole R.

Br J Psychiatry. 2011 May;198(5):341-5. doi: 10.1192/bjp.bp.109.075366. Review.

20.
Items per page

Supplemental Content

Write to the Help Desk